Equities

Dishman Carbogen Amcis Ltd

Dishman Carbogen Amcis Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)191.29
  • Today's Change7.59 / 4.13%
  • Shares traded863.04k
  • 1 Year change+23.41%
  • Beta1.8393
Data delayed at least 15 minutes, as of Sep 20 2024 11:28 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Dishman Carbogen Amcis Ltd had net income fall 414.93% from a loss of 298.00m to a larger loss of 1.53bn despite a 8.41% increase in revenues from 24.13bn to 26.16bn. An increase in the selling, general and administrative costs as a percentage of sales from 57.26% to 60.02% was a component in the falling net income despite rising revenues.
Gross margin79.30%
Net profit margin-10.27%
Operating margin-4.68%
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in INRView more

In 2024, Dishman Carbogen Amcis Ltd increased its cash reserves by 100.39%, or 1.32bn. The company earned 3.84bn from its operations for a Cash Flow Margin of 14.68%. In addition the company used 2.30bn on investing activities and also paid 221.50m in financing cash flows.
Cash flow per share1.10
Price/Cash flow per share165.73
Book value per share--
Tangible book value per share--
More ▼

Balance sheet in INRView more

Dishman Carbogen Amcis Ltd uses little or no debt in its capital structure.
Current ratio--
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼

Growth rates in INR

Year on year, growth in earnings per share excluding extraordinary items dropped -414.93%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
-1,377.17
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.